Date of application of new EU In Vitro Diagnostics Regulation
26 May 2022 marks the date of application of the new EU In Vitro Diagnostics Regulation (EU) 2017/746 and with it the most transformative regulatory framework impacting in vitro diagnostics in Europe.

Today marks the date of application of the new EU In Vitro Diagnostics Regulation (EU) 2017/746 and with it the most transformative regulatory framework impacting in vitro diagnostics in Europe.

We at Critical Catalyst welcome and celebrate this important milestone in the diagnostics field!

Our team will continue to lead the way on regulatory affairs support to in vitro diagnostics manufacturers, ensuring that vital diagnostic solutions comply with the requirements on safety and performance and remain available to healthcare professionals and patients.

Regulatory background

Medical devices, including in vitro medical devices, have a fundamental role in saving lives by providing healthcare solutions for the diagnosis, prevention, monitoring, prediction, prognosis, treatment or alleviation of a disease.
Regulation (EU) 2017/746 (IVDR) replaces Directive 98/79/EC (IVDD) and significantly reinforces the regulatory framework applicable to in vitro diagnostic medical devices.

Application of new In Vitro Diagnostics Regulation

As of today, new rules on in vitro diagnostic medical devices such as HIV tests, pregnancy tests or COVID-19 tests, will be applicable, aiming to better protect public health and patient safety in respect to these devices, bringing EU law in line with technological progress and medical advances. By aligning market access requirements in the different EU Member States, it also boosts a free and fair market access for manufacturers.

In summary, the new Regulation on in vitro diagnostic medical devices introduces several important advances:
– Improves the quality, safety and reliability of in vitro diagnostic medical devices with a new risk-based device classification system;

– More detailed and stringent rules on the evaluation of device performance;

– Greater involvement of independent conformity assessment bodies (‘notified bodies’). Additionally, panel of experts and EU reference laboratories can be involved in the assessment of the highest-risk in vitro diagnostics;

– A unique device identifier will be mandatory for every IVD to reinforce traceability through EUDAMED;

– For medium and high risk devices a Summary of Safety and Performance will be made publicly available;

– Enhances vigilance and post-market surveillance, with manufacturers having to proactively collect data about their performance and EU authorities closely coordinating their vigilance and market surveillance activities.

Some important notes:

Although five years have passed since the new IVDR first came into force, there are still some key aspects that are not fully in place concerning the sufficient infrastructure to support the new regulation, and in particular, the limited Notified Body capacity, which is why the regulation was amended in January 2022 to grant many existing IVDs a further three to five more years to transition to the new requirements. Regarding requirements application, the in vitro diagnostics are divided in three IVD categories, to which the IVDR applies differently:

– Old devices (devices placed on the market under the IVDD before the date of application);

– New devices (devices placed on the market under the IVDR, regardless of the date of application); and

– Legacy devices (devices with an IVDD CE certificate valid past the date of application and IVDD devices with a valid declaration of conformity issued before the date of application).

Regardless, the folowing requirements apply from 26 May 2022:

From 26 May 2022 all IVD manufacturers must:

– Update QMS to meet the IVDR.

– Update design control to include General Safety and Performance Requirements for new devices and significant changes.

– Implement Chapter VII of the IVDR post-market requirements including PMS Plan, PMS Report, PMPF and vigilance with trend reporting.

– Clinical performance studies according to Annex XII and XIV as appropriate and address ISO 20916.

– Appoint a Person Responsible for Regulatory Compliance (PRRC) before placing IVDs on the market under the IVDR.

– Register in EUDAMED, when applicable.

References:

Regulation (EU) 2017/746 on in vitro diagnostic medical devices.

MDCG 2022-8 – Regulation (EU) 2017/746 – application of IVDR requirements to ‘legacy devices’ and to devices placed on the market prior to 26 May 2022.


further
reading

medical devices

Amendments to the Transitional Provisions of the European Union MDR and IVDR

The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device – until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

Read More »
medical devices

EU MDR – Proposal for Extension of Transition Period

The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

Read More »
medical devices

MDCG 2022-18 – EU MDR Article 97

EU MDR Article 97 may be a temporary solution to avoid disruption of supply of Medical Devices on the EU Market. The MDCG 2022-18 presents a uniform approach for application of MDR Article 97 on non-compliant legacy devices under the conditions set by the competent authorities, while limiting the impact on the supply of safe and effective devices.

Read More »
parfum_fragrance_allergen_1
cosmetic products

EU to set Labelling Requirements for 56 additional Fragrance Allergens in Cosmetic Products

World Trade Organization (WTO) has been notified by the European Commission of a draft amendment to Regulation (EC) No 1223/2009 as regards labelling of fragrance allergens in Cosmetic Products. The proposed date of adoption of the new regulation is expected to be in the first half of 2023 and the propose date of entry in force 20 days from the publication in the Official Journal of the European Union.

Read More »
cosmetic products

New Amendments to the European Cosmetics Regulation – CMR Substances

The European Commission published the Commission Regulation (EU) 2022/1531, which amends Regulation (EC) No 1223/2009 in regards to the use in cosmetic products of certain substances classified as CMR. This amendment introduces new entries to Annex II and Annex III and revises an entry to Annex V to Regulation (EC) No 1223/2009.

Read More »
medical devices

EUDAMED – harmonized practices and alternative solutions for IVDR until the database is fully functional

EUDAMED is one of the key aspects of the new rules on in vitro diagnostic medical devices – Regulation (EU) 2017/746. However, it is only expected to achieve full functionality by the second quarter of 2024. Until then, how is the information submitted and/or exchanged between manufacturers, notified bodies and competent authorities?

Read More »
medical devices

EUDAMED – update on timelines

EUDAMED is one of the key aspects of the new rules on medical devices (Regulation (EU) 2017/745) and in vitro diagnostic medical devices (Regulation (EU) 2017/746), and it is expected to achieve full functionality by the second quarter of 2024.

Read More »
cosmetic products

UK OPSS call for data on six cosmetic ingredients

On 14 July 2022, the Office for Product Safety and Standards (OPSS – the UK regulator for cosmetic products) issued a call for data on the safety of the following six cosmetic ingredients to investigate any suspected endocrine disrupting properties. 

Read More »